Literature DB >> 29979473

Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study.

Audun Osland Vik-Mo1,2, Lasse Melvaer Giil1,3, Clive Ballard4, Dag Aarsland2,5.   

Abstract

OBJECTIVE: Neuropsychiatric symptoms (NPS) in dementia are frequent and challenging for patients, carers, and the health care system, but few long-term studies exist. We analyse the longitudinal course of NPS in patients with mild dementia.
METHODS: A longitudinal cohort study of 223 patients with mild dementia and annual assessments using the Neuropsychiatric Inventory (NPI) for 5 years.
RESULTS: A total 1043 NPI assessments, representing 97% of all possible measurements of living cohort members, were analysed. Neuropsychiatric symptoms were common at baseline, and only a moderate increase in total NPS score from 15 to 17 with no increase in the proportion with high NPI total scores. Ninety seven percent scored ≥16, and 49% scored ≥36 on NPI total score at least once during follow-up. Individual NPS fluctuated and often reappeared. The most common symptoms ever reported was apathy (83%), depression (63%), appetite (63%), and aberrant motor behavior (60%). Cognitive decline was associated with higher NPI total score and several NPI items, but only the frequency of apathy increased significantly with time. Lewy body dementia was associated with higher NPI total score and psychotic symptoms. Alzheimer's disease was associated with increase in apathy.
CONCLUSIONS: Severe NPS are already common at time of dementia diagnosis, and the increase in overall severity over 5 years was moderate. Individual symptoms tend to fluctuate over time within patients and correspond to states rather than traits. These findings highlight the need to focus on, and plan for, NPS as part of dementia pathway, and are relevant for clinical trial design.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer's disease; Lewy body dementia; Neuropsychiatric Inventory; behavioral disturbances; dementia; depression: apathy; longitudinal; neuropsychiatric symptoms; psychosis

Mesh:

Year:  2018        PMID: 29979473     DOI: 10.1002/gps.4933

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  14 in total

1.  Potentially Inappropriate Medications Pre- and Post-Diagnosis of Major Neurocognitive Disorders Among Older People in Sweden: A Register-Based, 6-Year Longitudinal Study.

Authors:  Eva Sönnerstam; Maria Gustafsson; Hugo Lövheim; Maria Sjölander
Journal:  Drugs Aging       Date:  2022-06-03       Impact factor: 4.271

Review 2.  Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.

Authors:  Zahinoor Ismail; Byron Creese; Dag Aarsland; Helen C Kales; Constantine G Lyketsos; Robert A Sweet; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2022-01-04       Impact factor: 44.711

3.  Free-Text Documentation of Dementia Symptoms in Home Healthcare: A Natural Language Processing Study.

Authors:  Maxim Topaz; Victoria Adams; Paula Wilson; Kyungmi Woo; Miriam Ryvicker
Journal:  Gerontol Geriatr Med       Date:  2020-09-24

4.  Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia.

Authors:  Lasse M Giil; Dag Aarsland; Audun Osland Vik-Mo
Journal:  Alzheimers Dement (Amst)       Date:  2021-02-20

5.  Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management.

Authors:  Luis Agüera-Ortiz; Rocío García-Ramos; Francisco J Grandas Pérez; Jorge López-Álvarez; José Manuel Montes Rodríguez; F Javier Olazarán Rodríguez; Javier Olivera Pueyo; Carmelo Pelegrin Valero; Jesús Porta-Etessam
Journal:  Front Psychiatry       Date:  2021-02-26       Impact factor: 4.157

6.  Network structures and temporal stability of self- and informant-rated affective symptoms in Alzheimer's disease.

Authors:  T T Saari; I Hallikainen; T Hintsa; A M Koivisto
Journal:  J Affect Disord       Date:  2020-07-19       Impact factor: 4.839

7.  Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?

Authors:  Victor Bloniecki; Henrik Zetterberg; Dag Aarsland; Patrizia Vannini; Hlin Kvartsberg; Bengt Winblad; Kaj Blennow; Yvonne Freund-Levi
Journal:  Alzheimers Res Ther       Date:  2020-11-17       Impact factor: 6.982

Review 8.  The Impact of COVID-19 Infection and Enforced Prolonged Social Isolation on Neuropsychiatric Symptoms in Older Adults With and Without Dementia: A Review.

Authors:  Riccardo Manca; Matteo De Marco; Annalena Venneri
Journal:  Front Psychiatry       Date:  2020-10-22       Impact factor: 4.157

9.  Embarking on a memory assessment voices of older persons living with memory impairment.

Authors:  Marie Tyrrell; Dorota Religa; Bjöörn Fossum; Ragnhild Hedman; Kirsti Skovdahl; Pernilla Hillerås
Journal:  Dementia (London)       Date:  2020-03-18

10.  Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.

Authors:  Jeffrey Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-10-28       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.